DELIVERED SIGNIFICANT IMPROVEMENT IN EASI SCORES

≥75% IMPROVEMENT IN LESION EXTENT AND SEVERITY
(EASI-75*) AT WEEK 81,2
≥75% IMPROVEMENT IN LESION EXTENT AND SEVERITY (EASI-75*) AT WEEK 81,2
Adapted from Papp K et al. doi:10.17632/ffx6nd5zyb.1. Licensed under CC BY 4.0.
>60% of patients
achieved EASI-75 at week 81
>60% of patients
achieved EASI-75 at week 81

Mild defined as EASI score 1.1–7.0.3
In TRuE-AD1 and TRuE-AD2, respectively, 46% and 50% of patients on OPZELURA vs 56% and 44% of patients on vehicle had a baseline EASI score of 1.1–7.0.4
*EASI-75 is defined as the achievement of at least 75% improvement in EASI score from baseline.1
BID=twice daily; EASI=Eczema Area and Severity Index.

See safety results >
References: 1. Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863-872. doi:10.1016/j.jaad.2021.04.085. 2. Papp K, Szepietowski JC, Kircik L, et al. Supplementary appendix, efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from two phase 3, randomized, double-blind studies. Mendeley Data. doi:10.17632/ffx6nd5zyb.1. 3. Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353-1357. 4. Data on file. Incyte Corporation. 2021.

improvement IN LESION EXTENT AND SEVERITY (EASI) AT WEEK 81
>70% mean improvement
in EASI score from baseline at week 81
>70% mean improvement
in EASI score from baseline at week 81

Mild defined as EASI score 1.1–7.0.3
In TRuE-AD1 and TRuE-AD2, respectively, 46% and 50% of patients on OPZELURA vs 56% and 44% of patients on vehicle had a baseline EASI score of 1.1–7.0.4
BID=twice daily; EASI=Eczema Area and Severity Index.

See safety results >
References: 1. Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863-872. doi:10.1016/j.jaad.2021.04.085. 2. Papp K, Szepietowski JC, Kircik L, et al. Supplementary appendix, efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from two phase 3, randomized, double-blind studies. Mendeley Data. doi:10.17632/ffx6nd5zyb.1. 3. Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353-1357. 4. Data on file. Incyte Corporation. 2021.

